Eastman Chemical Vs Albemarle: Which Stock Is A Better Pick?
Zacks Investment Research | Jul 07, 2017 05:36AM ET
The chemical industry has clawed its way back from the trough of the Great Recession. The highly cyclical industry put up a commendable performance in first-quarter 2017. A host of companies in the space posted better-than-expected earnings in the quarter, driven by strength in key chemical end-use markets and strategic measures including productivity improvement, pricing actions and earnings-accretive acquisitions.
The bullish Zacks Industry Rank of 37 carried by the Zacks categorized Chemicals-Diversified industry testifies that the chemical industry is in fine fettle. An impressive rank places the industry in the top 14% of the 250+ groups enlisted.
The Chemicals-Diversified industry has also outperformed the broader market over the past year. The industry has gained 21.6% over this period, higher than S&P 500’s corresponding return of 14%.
While the chemical industry still faces some challenges, its healthy momentum is expected to continue in the back half of 2017. The U.S. chemical industry remains on course for solid growth this year and the next. The American Chemistry Council (ACC), an industry trade group, envisions accelerated growth for the domestic chemical industry on the back of an improving global economy and a surge in shale-linked capital investment.
The European chemical industry is also showing signs of recovery after remaining in a rut for long. The business environment for the European chemical industry improved during the first quarter on the back of improving global economic sentiment.
In this write up, we run a comparative analysis on two prominent chemical payers – Eastman Chemical Company (NYSE:EMN) and Albemarle Corporation (NYSE:ALB) – to figure out which one is a better option for investment right now.
Eastman Chemical, sporting a Zacks Rank #2 (Buy), is a global chemical company boasting a broad portfolio of chemical, plastic, and fiber products with a market capitalization of $12.2 billion. Albemarle, also a Zacks Rank #2 stock, has a market capitalization of around $12 billion and is a premier specialty chemicals maker with leading positions in attractive end markets globally.
Let's take a closer look at how Eastman Chemical and Albemarle are stacked up against each other in terms of certain key metrics.
Price Performance
Eastman Chemical has gained 24.8% over the past year while Albemarle’s shares have rallied 32.9%. While both stocks have outperformed the Chemicals-Diversified industry over the same period, Albemarle clearly scores above Eastman Chemical.
Get The News You Want
Leverage & Liquidity
Albemarle has a lower leverage as evident by its debt to equity ratio of 0.37 compared with Eastman Chemical’s debt to equity ratio of 1.39.
In terms of liquidity (as determined by the current ratio), Albemarle also holds an edge over Eastman Chemical. The current ratio for Albemarle is 1.98 compared with 1.93 for Eastman Chemical.
Valuation
Going by the EV/EBITDA (Enterprise Value/ Earnings before Interest Tax Depreciation and Amortization) multiple, a preferred valuation metric for cyclical industries like chemicals, Eastman Chemical looks cheaper compared with Albemarle.
In case of Albemarle, the trailing 12-months EV/EBITDA multiple is 14.45, higher than the Chemicals-Diversified industry average trailing 12-months EV/EBITDA multiple of 10.72. On the other hand, Eastman Chemical is much cheaper with a trailing 12-month EV/EBITDA of 8.92.
Return on Equity (ROE)
ROE is a measure of a company’s efficiency in utilizing shareholder’s funds. ROE for the trailing 12-months for Eastman Chemical and Albemarle is 22.2% and 12%, respectively. While both stocks have scored below the industry’s level of 22.8%, Eastman Chemical holds an edge here.
Earnings Surprise History
Taking a look at both the companies surprise history, Albemarle has outpaced the Zacks Consensus Estimate in each of the trailing four quarters, with an average positive earnings surprise of 8.97%. On the other hand, Eastman Chemical has delivered positive earnings surprises in the three of the trailing four quarters, generating an average positive earnings surprise of 4.21%.
Estimate Revisions & Growth Expectations
Over the past 60 days, Eastman Chemical’s estimates for the current year has edged up 0.1% to $7.49 per share. On the other hand, Albemarle’s estimates for the current year increased 1.2% over the same period to $4.33.
The expected earnings per share growth rate for Eastman Chemical for the current year currently stands at 10.85% compared with an expected increase of 21.20% for Albemarle. Also, Albemarle has an expected long-term earnings growth of 14.4%, much higher than Eastman Chemical’s 7.9%. As such, Albemarle is a clear winner in terms of earnings growth expectations.
In Conclusion
Our comparative analysis shows that Eastman Chemical holds an edge over Albemarle in terms of valuation and ROE measures. However, when considering price performance, leverage, earnings surprise history and earnings growth projections, Albemarle seems to be the preferred stock. As the scale is tipped in favor of Albemarle, it makes a better investment proposition compared to Eastman Chemical.
Some Other Stocks to Consider
Apart from Albemarle, investors interested in the chemical space may also consider Kronos Worldwide, Inc. (NYSE:KRO) and Innospec Inc. (NASDAQ:IOSP) , both of which carry a Zacks Rank #1 (Strong Buy). You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.